Mealey's (September 19, 2017, 2:52 PM EDT) -- TOPEKA, Kan. — A motion to dismiss an EpiPen antitrust lawsuit continued to play out in two federal courts Sept. 14 when defendant Sanofi-Aventis U.S. LLC filed its opposition and defendant Mylan Inc. filed a reply (In Re: EpiPen Marketing, Sales Practices and Antitrust Litigation, MDL Docket No. 2785, No. 17-md-2785, D. Kan., and Sanofi-Aventis U.S. LLC v. Mylan, Inc., et al., No. 17-2763, D. N.J.)....